Benefits of PET or PET/CT Imaging Unproven in Recurrent Bowel Cancer
By MedImaging International staff writers Posted on 08 Jan 2013 |
For patients with a suspected recurrence of bowel cancer, recent available study data allow no clear conclusions as to the advantages and disadvantages of utilizing positron emission tomography (PET) imaging, either alone or in combination with computed tomography (CT).
These findings are resulted from the fact that there no studies have directly compared the benefits of these imaging techniques in recurrent colorectal carcinoma (bowel cancer) with traditional diagnostic techniques. Although PET or PET/CT show a higher diagnostic accuracy (i.e., in specific instance), recurrences can be detected more effectively, it is still not clear how this actually affects patient-relevant outcomes such as quality of life. This was the conclusion of the final report of the German Institute for Quality and Efficiency in Health Care (IQWiG; Cologne, Germany), published on October 24, 2012.
Bowel cancer is the second most common cancerous tumor in both men and women. Yearly, more than 65,000 people are diagnosed with the disease in Germany and more than 25,000 die from it annually. Approximately 80% of the recurrences occur in the first two years after surgery for bowel cancer. After five years, virtually no more recurrences were detected. These can occur at the original site—the bowel—or as secondary tumors (metastases), for example, in the liver. Follow-up after surgery should therefore continue for five years.
Many specialists hope that when a recurrence is suspected, using PET or PET/CT scanning alone or in combination with other methods is better able to differentiate between benign and malignant tumors (recurrence diagnostics) and, if confirmed, to categorize the stage of malignant tumors appropriately ( i.e., to determine how advanced the cancer is [recurrence staging]). This information should provide patients with better treatment recommendations.
IQWiG searched the international literature for studies that had examined the consequences of a diagnostic intervention using PET or PET/CT on health aspects of direct pertinence to patients. For example, the diagnostic investigation findings--and suitably customized treatment--could contribute to better chances of survival for patients, save them from unnecessary operations or additional diagnostic interventions, or improve their quality of life.
For the preliminary report, IQWiG had already made an additional search for studies in which the diagnostic accuracy and prognostic capacity of PET or PET/CT had been compared with other diagnostic techniques. This referred to the question as to how frequently a PET study provides a correct finding.
The findings of a total of five evidence syntheses and 13 individual studies regarding this question could be assessed. The conclusion on recurrence detection was that PET and PET/CT appear capable of detecting or excluding recurrences more effectively than a traditional diagnostic intervention consisting solely or mostly on CT findings. This applies especially to local recurrences and distant metastases. It is not possible to state with conviction whether PET and PET/CT vary in terms of their diagnostic accuracy.
Significant questions in relation to PET technology remain unresolved. It has not yet been studied, for example, whether the higher accuracy of PET or PET/CT has a positive effect on mortality, the burden of disease, or quality of life. As long as this lack of data remains, a patient-relevant benefit of PET or of PET/CT as an adjunct to a suspicion-driven diagnostic study with traditional modalities is not validated. For instance, it is particularly not known whether a recurrence detected by using PET or PET/CT can actually be better treated and thereby generate a noticeable advantage for patients. Experts are therefore keenly awaiting the results of a Canadian study with more than 400 patients, which is to be published shortly.
Stefan Lange, the deputy director of IQWiG, commented on the new data gleaned by IQWiG during the evaluation procedure of the study on laparotomies, “The fact that the only benefit study on PET turned out to be unsuitable is extremely regrettable. The rupture of the logical link between diagnosis and treatment devalued the study results.”
As Mr. Lange explained, a fundamental principle of medicine is that a diagnostic intervention is only of benefit if it enables patients to receive more customized treatment.
Related Links:
German Institute for Quality and Efficiency in Health Care
These findings are resulted from the fact that there no studies have directly compared the benefits of these imaging techniques in recurrent colorectal carcinoma (bowel cancer) with traditional diagnostic techniques. Although PET or PET/CT show a higher diagnostic accuracy (i.e., in specific instance), recurrences can be detected more effectively, it is still not clear how this actually affects patient-relevant outcomes such as quality of life. This was the conclusion of the final report of the German Institute for Quality and Efficiency in Health Care (IQWiG; Cologne, Germany), published on October 24, 2012.
Bowel cancer is the second most common cancerous tumor in both men and women. Yearly, more than 65,000 people are diagnosed with the disease in Germany and more than 25,000 die from it annually. Approximately 80% of the recurrences occur in the first two years after surgery for bowel cancer. After five years, virtually no more recurrences were detected. These can occur at the original site—the bowel—or as secondary tumors (metastases), for example, in the liver. Follow-up after surgery should therefore continue for five years.
Many specialists hope that when a recurrence is suspected, using PET or PET/CT scanning alone or in combination with other methods is better able to differentiate between benign and malignant tumors (recurrence diagnostics) and, if confirmed, to categorize the stage of malignant tumors appropriately ( i.e., to determine how advanced the cancer is [recurrence staging]). This information should provide patients with better treatment recommendations.
IQWiG searched the international literature for studies that had examined the consequences of a diagnostic intervention using PET or PET/CT on health aspects of direct pertinence to patients. For example, the diagnostic investigation findings--and suitably customized treatment--could contribute to better chances of survival for patients, save them from unnecessary operations or additional diagnostic interventions, or improve their quality of life.
For the preliminary report, IQWiG had already made an additional search for studies in which the diagnostic accuracy and prognostic capacity of PET or PET/CT had been compared with other diagnostic techniques. This referred to the question as to how frequently a PET study provides a correct finding.
The findings of a total of five evidence syntheses and 13 individual studies regarding this question could be assessed. The conclusion on recurrence detection was that PET and PET/CT appear capable of detecting or excluding recurrences more effectively than a traditional diagnostic intervention consisting solely or mostly on CT findings. This applies especially to local recurrences and distant metastases. It is not possible to state with conviction whether PET and PET/CT vary in terms of their diagnostic accuracy.
Significant questions in relation to PET technology remain unresolved. It has not yet been studied, for example, whether the higher accuracy of PET or PET/CT has a positive effect on mortality, the burden of disease, or quality of life. As long as this lack of data remains, a patient-relevant benefit of PET or of PET/CT as an adjunct to a suspicion-driven diagnostic study with traditional modalities is not validated. For instance, it is particularly not known whether a recurrence detected by using PET or PET/CT can actually be better treated and thereby generate a noticeable advantage for patients. Experts are therefore keenly awaiting the results of a Canadian study with more than 400 patients, which is to be published shortly.
Stefan Lange, the deputy director of IQWiG, commented on the new data gleaned by IQWiG during the evaluation procedure of the study on laparotomies, “The fact that the only benefit study on PET turned out to be unsuitable is extremely regrettable. The rupture of the logical link between diagnosis and treatment devalued the study results.”
As Mr. Lange explained, a fundamental principle of medicine is that a diagnostic intervention is only of benefit if it enables patients to receive more customized treatment.
Related Links:
German Institute for Quality and Efficiency in Health Care
Latest Nuclear Medicine News
- Novel Radiolabeled Antibody Improves Diagnosis and Treatment of Solid Tumors
- Novel PET Imaging Approach Offers Never-Before-Seen View of Neuroinflammation
- Novel Radiotracer Identifies Biomarker for Triple-Negative Breast Cancer
- Innovative PET Imaging Technique to Help Diagnose Neurodegeneration
- New Molecular Imaging Test to Improve Lung Cancer Diagnosis
- Novel PET Technique Visualizes Spinal Cord Injuries to Predict Recovery
- Next-Gen Tau Radiotracers Outperform FDA-Approved Imaging Agents in Detecting Alzheimer’s
- Breakthrough Method Detects Inflammation in Body Using PET Imaging
- Advanced Imaging Reveals Hidden Metastases in High-Risk Prostate Cancer Patients
- Combining Advanced Imaging Technologies Offers Breakthrough in Glioblastoma Treatment
- New Molecular Imaging Agent Accurately Identifies Crucial Cancer Biomarker
- New Scans Light Up Aggressive Tumors for Better Treatment
- AI Stroke Brain Scan Readings Twice as Accurate as Current Method
- AI Analysis of PET/CT Images Predicts Side Effects of Immunotherapy in Lung Cancer
- New Imaging Agent to Drive Step-Change for Brain Cancer Imaging
- Portable PET Scanner to Detect Earliest Stages of Alzheimer’s Disease
Channels
Radiography
view channel
AI Improves Early Detection of Interval Breast Cancers
Interval breast cancers, which occur between routine screenings, are easier to treat when detected earlier. Early detection can reduce the need for aggressive treatments and improve the chances of better outcomes.... Read more
World's Largest Class Single Crystal Diamond Radiation Detector Opens New Possibilities for Diagnostic Imaging
Diamonds possess ideal physical properties for radiation detection, such as exceptional thermal and chemical stability along with a quick response time. Made of carbon with an atomic number of six, diamonds... Read moreMRI
view channel
Cutting-Edge MRI Technology to Revolutionize Diagnosis of Common Heart Problem
Aortic stenosis is a common and potentially life-threatening heart condition. It occurs when the aortic valve, which regulates blood flow from the heart to the rest of the body, becomes stiff and narrow.... Read more
New MRI Technique Reveals True Heart Age to Prevent Attacks and Strokes
Heart disease remains one of the leading causes of death worldwide. Individuals with conditions such as diabetes or obesity often experience accelerated aging of their hearts, sometimes by decades.... Read more
AI Tool Predicts Relapse of Pediatric Brain Cancer from Brain MRI Scans
Many pediatric gliomas are treatable with surgery alone, but relapses can be catastrophic. Predicting which patients are at risk for recurrence remains challenging, leading to frequent follow-ups with... Read more
AI Tool Tracks Effectiveness of Multiple Sclerosis Treatments Using Brain MRI Scans
Multiple sclerosis (MS) is a condition in which the immune system attacks the brain and spinal cord, leading to impairments in movement, sensation, and cognition. Magnetic Resonance Imaging (MRI) markers... Read moreUltrasound
view channel.jpeg)
AI-Powered Lung Ultrasound Outperforms Human Experts in Tuberculosis Diagnosis
Despite global declines in tuberculosis (TB) rates in previous years, the incidence of TB rose by 4.6% from 2020 to 2023. Early screening and rapid diagnosis are essential elements of the World Health... Read more
AI Identifies Heart Valve Disease from Common Imaging Test
Tricuspid regurgitation is a condition where the heart's tricuspid valve does not close completely during contraction, leading to backward blood flow, which can result in heart failure. A new artificial... Read moreGeneral/Advanced Imaging
view channel
AI-Based CT Scan Analysis Predicts Early-Stage Kidney Damage Due to Cancer Treatments
Radioligand therapy, a form of targeted nuclear medicine, has recently gained attention for its potential in treating specific types of tumors. However, one of the potential side effects of this therapy... Read more
CT-Based Deep Learning-Driven Tool to Enhance Liver Cancer Diagnosis
Medical imaging, such as computed tomography (CT) scans, plays a crucial role in oncology, offering essential data for cancer detection, treatment planning, and monitoring of response to therapies.... Read moreImaging IT
view channel
New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible
Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
Global AI in Medical Diagnostics Market to Be Driven by Demand for Image Recognition in Radiology
The global artificial intelligence (AI) in medical diagnostics market is expanding with early disease detection being one of its key applications and image recognition becoming a compelling consumer proposition... Read moreIndustry News
view channel
GE HealthCare and NVIDIA Collaboration to Reimagine Diagnostic Imaging
GE HealthCare (Chicago, IL, USA) has entered into a collaboration with NVIDIA (Santa Clara, CA, USA), expanding the existing relationship between the two companies to focus on pioneering innovation in... Read more
Patient-Specific 3D-Printed Phantoms Transform CT Imaging
New research has highlighted how anatomically precise, patient-specific 3D-printed phantoms are proving to be scalable, cost-effective, and efficient tools in the development of new CT scan algorithms... Read more
Siemens and Sectra Collaborate on Enhancing Radiology Workflows
Siemens Healthineers (Forchheim, Germany) and Sectra (Linköping, Sweden) have entered into a collaboration aimed at enhancing radiologists' diagnostic capabilities and, in turn, improving patient care... Read more